default author photo

Ying Yuan

University of Texas at Houston - MD Anderson Cancer Center

SCHOLARLY PAPERS

3

DOWNLOADS

88

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer

Number of pages: 44 Posted: 28 Mar 2024
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Texas Oncology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Texas Oncology, University of Texas at Houston - Department of Genomic Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 49 (1,074,648)

Abstract:

Loading...

pembrolizumab, combination chemotherapy, ovarian cancer, immunotherapy, tumor immune microenvironment, translational, clinical trial, feasibility

2.

Assessing the Role of Correlation between Efficacy and Toxicity Endpoints in the Performance of Bayesian Optimal Phase Ii Design

Number of pages: 24 Posted: 09 Feb 2025
Xun Xu, Ying Yuan and J. Jack Lee
affiliation not provided to SSRN, University of Texas at Houston - MD Anderson Cancer Center and The University of Texas MD Anderson Cancer Center - Department of Biostatistics
Downloads 20 (1,470,786)

Abstract:

Loading...

Bayesian adaptive design, efficacy-toxicity tradeoff, data analysis stage, design stage, phi coefficient, sensitivity analysis

3.

Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer

Number of pages: 27 Posted: 01 Feb 2024
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Aravive Biologics, Inc., Aravive Biologics, Inc., University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 19 (1,459,862)

Abstract:

Loading...

immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer